122 related articles for article (PubMed ID: 34723441)
21. The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation.
Robertson C; Arcot Ragupathy SK; Boachie C; Dixon JM; Fraser C; Hernández R; Heys S; Jack W; Kerr GR; Lawrence G; MacLennan G; Maxwell A; McGregor J; Mowatt G; Pinder S; Ternent L; Thomas RE; Vale L; Wilson R; Zhu S; Gilbert FJ
Health Technol Assess; 2011 Sep; 15(34):v-vi, 1-322. PubMed ID: 21951942
[TBL] [Abstract][Full Text] [Related]
22. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
23. Baseline radiological staging in primary breast cancer: impact of educational interventions on adherence to published guidelines.
McWhirter E; Yogendran G; Wright F; Pharm GD; Clemons M;
J Eval Clin Pract; 2007 Aug; 13(4):647-50. PubMed ID: 17683309
[TBL] [Abstract][Full Text] [Related]
24. Validation Study of the AJCC Cancer Staging Manual, Eighth Edition, Staging System for Eyelid and Periocular Squamous Cell Carcinoma.
Xu S; Sagiv O; Rubin ML; Sa HS; Tetzlaff MT; Nagarajan P; Ning J; Esmaeli B
JAMA Ophthalmol; 2019 May; 137(5):537-542. PubMed ID: 30869769
[TBL] [Abstract][Full Text] [Related]
25. A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer.
Lovrics PJ; Chen V; Coates G; Cornacchi SD; Goldsmith CH; Law C; Levine MN; Sanders K; Tandan VR
Ann Surg Oncol; 2004 Sep; 11(9):846-53. PubMed ID: 15313737
[TBL] [Abstract][Full Text] [Related]
26. 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques.
Koolen BB; Vrancken Peeters MJ; Aukema TS; Vogel WV; Oldenburg HS; van der Hage JA; Hoefnagel CA; Stokkel MP; Loo CE; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
Breast Cancer Res Treat; 2012 Jan; 131(1):117-26. PubMed ID: 21935602
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
[TBL] [Abstract][Full Text] [Related]
28. The Prognostic Value of the AJCC 8th Edition Staging System for Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer.
Kantor O; Bao J; Jaskowiak N; Yao K; Tseng J
Ann Surg Oncol; 2020 Feb; 27(2):352-358. PubMed ID: 31376037
[TBL] [Abstract][Full Text] [Related]
29. Routinely staging gastric cancer with
Findlay JM; Antonowicz S; Segaran A; El Kafsi J; Zhang A; Bradley KM; Gillies RS; Maynard ND; Middleton MR
Eur Radiol; 2019 May; 29(5):2490-2498. PubMed ID: 30643947
[TBL] [Abstract][Full Text] [Related]
30. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
31. Staging studies have limited utility for newly diagnosed stage I-II breast cancer.
Linkugel A; Margenthaler J; Dull B; Cyr A
J Surg Res; 2015 Jun; 196(1):33-8. PubMed ID: 25824669
[TBL] [Abstract][Full Text] [Related]
32. Changes of breast cancer staging when AJCC prognostic staging manual is used: a retrospective analysis of a Chinese cohort.
Ding J; Wu W; Fang J; Chu Y; Zheng S; Jiang L
Int J Biol Markers; 2018 May; 33(2):168-173. PubMed ID: 28967067
[TBL] [Abstract][Full Text] [Related]
33. Classification and staging of melanoma.
Gershenwald JE; Buzaid AC; Ross MI
Hematol Oncol Clin North Am; 1998 Aug; 12(4):737-65. PubMed ID: 9759577
[TBL] [Abstract][Full Text] [Related]
34. Use and Yield of Baseline Imaging and Laboratory Testing in Stage II Breast Cancer.
Bychkovsky BL; Guo H; Sutton J; Spring L; Faig J; Dagogo-Jack I; Battelli C; Houlihan MJ; Yeh TC; Come SE; Lin NU
Oncologist; 2016 Dec; 21(12):1495-1501. PubMed ID: 27551013
[TBL] [Abstract][Full Text] [Related]
35. The Prognostic Value of the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging System in HER2-Enriched Subtype Breast Cancer, a Retrospective Analysis.
Zhou B; Xu L; Ye J; Xin L; Duan X; Liu Y
Anticancer Res; 2017 Aug; 37(8):4615-4621. PubMed ID: 28739761
[TBL] [Abstract][Full Text] [Related]
36. Influence of genomics on adjuvant treatments for pre-invasive and invasive breast cancer.
Abu-Khalf M; Pusztai L
Breast; 2013 Aug; 22 Suppl 2():S83-7. PubMed ID: 24074799
[TBL] [Abstract][Full Text] [Related]
37. Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years.
Riedl CC; Slobod E; Jochelson M; Morrow M; Goldman DA; Gonen M; Weber WA; Ulaner GA
J Nucl Med; 2014 Oct; 55(10):1578-83. PubMed ID: 25214641
[TBL] [Abstract][Full Text] [Related]
38. Impact of 21-Gene Expression Assay on Staging Estrogen Receptor-Positive HER2-Negative Breast Cancer.
Breaux A; Turner B; Wu X; Rai SN; Riley EC; Mandadi M; Sanders MA
Clin Breast Cancer; 2019 Feb; 19(1):e261-e269. PubMed ID: 30509870
[TBL] [Abstract][Full Text] [Related]
39. Validation of the pathological prognostic staging system proposed in the revised eighth edition of the AJCC staging manual in different molecular subtypes of breast cancer.
Jang N; Choi JE; Kang SH; Bae YK
Virchows Arch; 2019 Feb; 474(2):193-200. PubMed ID: 30474738
[TBL] [Abstract][Full Text] [Related]
40. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.
Ulaner GA; Castillo R; Goldman DA; Wills J; Riedl CC; Pinker-Domenig K; Jochelson MS; Gönen M
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1937-44. PubMed ID: 27129866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]